Aqemia is a next-generation pharmatech company founded in 2019 as a deeptech spinoff from École Normale Supérieure that revolutionizes drug discovery by combining quantum-inspired physics algorithms with generative AI, enabling molecule exploration 10,000 times faster than conventional methods without requiring experimental training data, generating its own molecular data from first principles to guide AI-driven drug candidate discovery, with over $100 million in funding and major partnerships including a $140 million collaboration with Sanofi to accelerate oncology drug development through physics-based molecular design.
Maximilien Levesque (Co-founder, CEO), Emmanuel Briet (Co-founder, CTO)
Explore other quantum computing companies in similar categories or regions.
Private
$200M
2 funding rounds tracked. View detailed investment history →